Scarica l'app Stockscreener
70.50
1.39%
0.965
Pre-mercato:
68.00
-2.495
-3.54%
Precedente Chiudi:
$69.53
Aprire:
$69.53
Volume 24 ore:
37,315
Relative Volume:
0.97
Capitalizzazione di mercato:
$96.72M
Reddito:
$697.00K
Utile/perdita netta:
$-38.97M
Rapporto P/E:
-2.4246
EPS:
-29.075
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
+2.00%
1M Prestazione:
+30.05%
6M Prestazione:
+719.71%
1 anno Prestazione:
-90.34%
Intervallo 1D:
$67.50
$71.56
Intervallo di 1 settimana:
$55.98
$71.56
Portata 52W:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
70.50 | 96.72M | 697.00K | -38.97M | -33.33M | -29.07 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
SPRB SEC FilingsSpruce Biosciences, Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
Spruce Biosciences, Inc. (SPRB) stock price, news, quote and history - Yahoo Finance UK
Wall Street experts predict that Spruce Biosciences (SPRB) may surge by 181.21%: Strategies for Trading - Bitget
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - Yahoo Finance
SPRB Earnings History & Surprises | EPS & Revenue Results | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
SPRB Forecast, Price Target & Analyst Ratings | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - MSN
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spruce Stock Ignites: A 24% Surge Defies Gravity as Energy Winds Shift - Bitget
Citizens reiterates Spruce Biosciences stock rating on approval outlook - Investing.com
Citizens reiterates Spruce Biosciences stock rating on approval outlook By Investing.com - Investing.com India
Spruce Biosciences Reports 2025 Financial Results, Advances TA-ERT Toward FDA Approval for MPS IIIB and Secures $50M Growth Capital - Minichart
Spruce Biosciences to end collaboration agreement with Kaken Pharmaceutical - Investing.com
Spruce Biosciences On March 16, Entered Termination Agreement With Kaken PharmaceuticalSEC Filing - TradingView
Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline - tipranks.com
Spruce Biosciences, Inc. announced that all license agreements and corresponding rights previously signed with Kaken Pharmaceutical Co., Ltd. will be terminated. - Bitget
Spruce Biosciences (Nasdaq: SPRB) cuts 2025 loss, exits Kaken pact to focus TA-ERT - Stock Titan
Spruce Biosciences (SPRB) appoints Dale Hooks as CCO and reports narrowed $39M 2025 net loss - msn.com
Does Spruce Biosciences (SPRB) have the potential to rally 208.32% as Wall Street analysts expect? - MSN
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect? - Zacks Investment Research
Is There a Chance for Spruce Biosciences (SPRB) to Surge by 208.32% According to Wall Street Analysts? - Bitget
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss - Insider Monkey
Spruce Biosciences names Dale Hooks as chief commercial officer - Investing.com Nigeria
HC Wainwright Issues Optimistic Outlook for SPRB Earnings - MarketBeat
Oppenheimer Remains a Buy on Spruce Biosciences (SPRB) - The Globe and Mail
SPRB: Citizens Lowers Price Target but Maintains Market Outperfo - GuruFocus
SPRB: Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum - TradingView
Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Given New $170.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Earns "Buy" Rating from HC Wainwright - MarketBeat
SPRB: HC Wainwright & Co. Reiterates Buy Rating with $200 PT | S - GuruFocus
Spruce Biosciences Reports 2025 Financial Results, Advances TA-ERT for MPS IIIB with FDA, and Secures $50M Growth Capital - Minichart
Spruce Biosciences names Dale Hooks as chief commercial officer By Investing.com - Investing.com Canada
[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Spruce Biosciences (SPRB) Chief Commercial Officer files Form 3 - Stock Titan
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Com - PharmiWeb.com
Spruce Biosciences, Inc. 2024 Annual Report: Business Overview, Risk Factors, Pipeline, and Regulatory Updates - Minichart
SPRB: TA-ERT program progresses toward BLA submission as net loss narrows and cash runway extends - TradingView
SPRB: TA-ERT is BLA-ready for MPS IIIB, with durable efficacy, safety, and strong market potential - TradingView
Spruce Biosciences Appoints Dale Hooks as Chief Commercial Officer - Contract Pharma
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - pharmiweb.com
According to the latest documents submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Spruce Biosciences, Inc. has been authorized to offer and sell its common stock under the current sales agreement, with the tota - Bitget
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):